Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$25.0M | -$25.2M | -$22.5M |
| Net income | -$24.7M | -$27.3M | -$22.2M |
| EPS (diluted) | -$17.24 | -$3.26 | -$1.06 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$21.6M | -$21.8M | -$19.2M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $2.96M | $8.64M | $13.2M |
| Total assets | $3.00M | $9.32M | $14.0M |
| Total liabilities | $8.44M | $9.21M | $6.11M |
| Shareholders' equity | -$99.6M | $104K | $7.92M |
| Retained earnings | -$105M | -$132M | -$155M |
| Shares (wtd avg diluted) | 1.43M | 8.37M | 21.0M |
Every figure is extracted from ACTUATE THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.